These observations suggest that aldometanib activates AMPK to revert the tumor environment to a state that enables migration of immune cells, thereby acting as leverage for the immune system to defend against cancer development, enabling cancer-bearing mice to live to maturity. Here, PRKAA2 is linked to neoplasm.